MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy. (Q54282269)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Fabricio de Carvalho

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Veruska L F Alves

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Walter M T Braga

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Celso V Xavier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

22 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

191-195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

Current concepts of clinical management of multiple myeloma.

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Abdominal manifestations of extraosseous myeloma: cross-sectional imaging spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

New insights into therapeutic targets in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

The genetic architecture of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Cancer/testis antigens, gametogenesis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Genome-wide analysis of cancer/testis gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

Cancer/testis (CT) antigens: potential targets for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1376-4

10.1007/S00262-012-1376-4

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23180015%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference